Agilent Technologies, Inc. (A) Stock Price & Analysis
Agilent Technologies, Inc. (A) closed at USD 173.89 on Thursday, October 22, 2026, down 2.17% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 177.75; the Oct 22, 2026 session ranged USD 171.23–179 on volume of 2,654,506 shares. Market capitalization is $49.03B, with a 52-week range of USD 108.35–179.1 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/A.md
Key facts (A)
- Last four reported quarters (through Jul 31, 2026): revenue $7.37B, net income $1.44B (19.5% margin), free cash flow $1.27B (SEC filings).
- Valuation: P/E 34.0x (avg 28.7x at the last 3 fiscal year-ends), EV/EBITDA 26.8x, net debt $2.19B.
- 2 of 80 tracked superinvestors hold A (13F, Q2 2026): 0 new, 0 added, 1 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $313K; 2 not under a Rule 10b5-1 plan ($313K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +18.8% vs S&P 500 +14.9%; 5Y +14.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-25, EPS estimate USD 1.73, revenue estimate $1.99B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (A)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.32B | $6.85B | $6.83B | $6.51B | $6.95B | $7.37B |
| Gross profit | $3.41B | $3.72B | $3.46B | $3.54B | $3.64B | — |
| Operating income | $1.35B | $1.62B | $1.35B | $1.49B | $1.48B | $1.64B |
| Net income | $1.21B | $1.25B | $1.24B | $1.29B | $1.30B | $1.44B |
| EPS (diluted) | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 | — |
| Free cash flow | $1.30B | $1.02B | $1.47B | $1.37B | $1.15B | $1.27B |
| Gross margin | 53.9% | 54.4% | 50.7% | 54.3% | 52.4% | — |
| Operating margin | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% | 22.2% |
| Net margin | 19.1% | 18.3% | 18.1% | 19.8% | 18.8% | 19.5% |
| Revenue growth | +18.4% | +8.4% | -0.2% | -4.7% | +6.7% | — |
| Cash + short-term investments | $1.48B | $1.05B | $1.59B | $1.33B | $1.79B | — |
| Total debt | $2.73B | $2.77B | $2.73B | $3.39B | $3.35B | — |
Fiscal years end Oct. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 31, 2026) (A)
P/E 34.0x · P/S 6.7x · EV/EBITDA 26.8x · EV/Sales 7.0x · P/FCF 38.7x · P/B 6.7x · FCF yield 2.58% · Earnings yield 2.94% · Dividend yield (paid, TTM) 0.58% · Buyback yield (TTM) 0.78% · Net debt $2.19B · EV $51.2B
P/E at fiscal year-ends: Oct 2025 32.0x, Oct 2024 29.4x, Oct 2023 24.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (A)
2 of 80 tracked investors hold A. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| William Von Mueffling | Cantillon Capital Management | 2.53% | $16.8M | Reduced -95.4% |
| Greenhaven Associates | 0.02% | $1.4M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (A)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Dolsten Mikael | Director | 634 | $96K | 11.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-29 | Dolsten Mikael | Director | 1,600 | $217K | 22.4% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (A)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $180 → $196 |
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $175 → $190 |
| 2026-10-07 | Barclays | Target raised | Overweight | $175 → $195 |
| 2026-08-28 | Wells Fargo | Target raised | Overweight | $160 → $180 |
| 2026-08-27 | Stifel | Target raised | Buy | $170 → $180 |
| 2026-08-27 | B of A Securities | Target raised | Buy | $155 → $180 |
| 2026-08-27 | Citigroup | Target raised | Buy | $185 → $190 |
| 2026-08-27 | Goldman Sachs | Target raised | Buy | $155 → $175 |
| 2026-08-27 | JP Morgan | Target raised | Overweight | $180 → $190 |
| 2026-08-27 | TD Cowen | Target raised | Buy | $155 → $180 |
| 2026-08-27 | Bernstein | Target raised | Outperform | $155 → $180 |
| 2026-08-27 | RBC Capital | Target raised | Outperform | $155 → $185 |
Total return (dividends reinvested) (A)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +18.8% | +14.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +18.9% | +2.7% |
| Volatility (annualized) | 31.9% | 29.6% |
| Max drawdown | -29.8% (Nov 2025→Mar 2026) | -36.6% (Nov 2021→Oct 2023) |
A revenue by business segment (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Agilent CrossLab | $786.0M | 41.9% | +5.6% |
| Life Sciences and Diagnostics Markets | $746.0M | 39.7% | +11.3% |
| Applied Markets | $346.0M | 18.4% | +6.8% |
| Total revenue | $1.88B | 100% | — |
A revenue by product line (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $1.33B | 71.0% | +8.4% |
| Non-Instrumentation and Other | $1.24B | 65.8% | +8.4% |
| Instrumentation | $643.0M | 34.2% | +7.3% |
| Services and Other | $545.0M | 29.0% | +7.3% |
| Total revenue | $1.88B | 100% | — |
A revenue by region (quarter ended Jul 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Americas | $761.0M | 40.5% | +11.4% |
| Asia Pacific | $613.0M | 32.6% | +8.9% |
| Europe | $504.0M | 26.8% | +2.4% |
| Total revenue | $1.88B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name A in their SEC reports
| Relationship to A | Company | Filing | Sentence |
|---|---|---|---|
| customer | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K Feb 12, 2026 | “In 2020, we amended our commercial supply agreement with Agilent to provide for Agilent to supply, subject to any conflicting obligations under our third-party agreements, a specified percentage of the API for certain of our commercial products.” |
A company outlook (results filed Aug 26, 2026)
- “Non-GAAP EPS (4) is expected in the range of $1.71 to $1.74 per share.”
- “This guidance does not include any future benefit from tariff refunds.”
- “All of this gives us confidence in our increased outlook and our ability to sustainably outperform our end markets." Financial Highlights Life Sciences and Diagnostics Markets Group The Life Sciences and Diagnostics Markets Group (LDG) reported third-quarter revenue of $746 million, growth of 11% reported and 10% core (1) year-over-year.”
- “The forward-looking statements contained herein include, but are not limited to, information regarding Agilent's growth prospects, business, financial results, revenue, non-GAAP earnings guidance for fiscal year and fourth-quarter 2026, and the effects of its operational transformation and customer and market-focused strategy.”
Quoted word-for-word from the SEC 8-K results press release.
A analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Oct 2026) | $1.73 | $1.72 | +0.7% | $1.99B | 17 |
| Next quarter (ends Jan 2027) | $1.50 | $1.51 | -1.1% | $1.93B | 10 |
| Current fiscal year (ends Oct 2026) | $6.20 | $6.06 | +2.4% | $7.50B | 20 |
| Next fiscal year (ends Oct 2027) | $6.74 | $6.61 | +2.0% | $7.98B | 21 |
A options: expected move
Options price a move of about ±12.2% (±$21.25) by Dec 18, 2026, which includes earnings on Nov 25, 2026; the earnings reaction alone is priced at about ±4.3%. Over the last 8 reports the stock moved ±4.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 36.5% | ±8.3% |
| Dec 18, 2026 | 56 | 38.7% | ±12.2% |
| Jan 15, 2027 | 84 | 35.3% | ±13.6% |
| Feb 19, 2027 | 119 | 35.8% | ±16.4% |
| Mar 19, 2027 | 147 | 35.9% | ±18.3% |
| May 21, 2027 | 210 | 35.7% | ±21.6% |
| Jun 17, 2027 | 237 | 36.3% | ±23.4% |
| Sep 17, 2027 | 329 | 36.2% | ±27.4% |
30-day implied volatility 34.8% vs 29.3% realized over the last 30 trading days. Put/call ratio (volume) 2.28. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 173.89 |
|---|---|
| Change | ▼ 2.17% (down) |
| Previous Close | USD 177.75 |
| Open | USD 177.5 |
| Day Range | USD 171.23 – 179 |
| 52-Week Range | USD 108.35 – 179.1 |
| Volume | 2,654,506 shares |
| Market Cap | $49.03B |
| Exchange | NYQ |
Technical Analysis (A)
Nexqual's technical model rates A "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.5 (neutral) |
| vs SMA50 | Above (USD 160.94) |
| MACD | 4.02 (positive) |
Earnings (A)
| Next Earnings Date | 2026-11-25 |
|---|---|
| EPS Estimate | USD 1.73 |
| Revenue Estimate | $1.99B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD 1.62 vs est 1.49 ▲ beat |
| 2026-04-30 | USD 1.49 vs est 1.41 ▲ beat |
| 2026-01-31 | USD 1.36 vs est 1.37 ▼ miss |
| 2025-10-31 | USD 1.59 vs est 1.58 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (A)
| Total Revenue | $7.37B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.10% |
| Gross Margin | +53.65% |
| Operating Margin | +25.56% |
| Profit Margin | +19.53% |
| ROE | +20.97% |
| Debt / Equity | 0.56 |
| Current Ratio | 2.05 |
| Total Cash | $1.76B |
| Total Debt | $4.15B |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $1.27B (17.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financial Health Score (A)
Nexqual rates Agilent Technologies, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:49 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 54%, operating 26% (last 12 months) |
| Balance Sheet | Strong — $1.76B cash and investments vs $3.95B debt (Jul 2026, SEC) |
| Cash Flow | Strong — FCF $1.27B (last 4 quarters to Jul 2026, SEC), 17% margin |
| Efficiency | Strong — ROE 21%, ROA 8.6% |
Ownership (A)
| Insider Ownership | +0.19% |
|---|---|
| Institutional Ownership | +95.57% |
| Shares Outstanding | 281.97M |
| Float | 280.96M |
| Short % of Float | +2.11% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
From Agilent Technologies, Inc.'s Latest SEC 10-K Filing (filed 2025-12-22)
Key Strengths & Strategy (as disclosed to the SEC)
- We offer a broad range of market specific consumables and supplies to complete customers' analytical workflows from sample preparation through separation and analysis to storage, with the support of our technology platforms.
- Our long-term relationships with suppliers allow us to proactively manage technology road maps and product discontinuance plans and monitor their financial health.
Legal & Regulatory Risks (Item 1A, quoted)
- Our customers and we are subject to various governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
- We are subject to extensive regulation by the Food and Drug Administration and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.
- Our business may suffer if we fail to comply with government contracting laws and regulations.
- Our reputation, ability to do business and financial statements may be harmed by improper conduct by any of our employees, agents or business partners.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IQV | IQVIA Holdings, Inc. | USD 278.32 | ▲ 0.61% |
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IDXX | IDEXX Laboratories, Inc. | USD 566.76 | ▲ 2.4% |
| ILMN | Illumina, Inc. | USD 269.4 | ▼ 4.76% |
| NTRA | Natera, Inc. | USD 401.37 | ▼ 2.91% |
| MTD | Mettler-Toledo International, I | USD 1,684.64 | ▲ 0.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt